Fig. 2: Expression of SAMHD1 protein in AML blasts. | Blood Cancer Journal

Fig. 2: Expression of SAMHD1 protein in AML blasts.

From: Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens

Fig. 2

a, b. SAMHD1 is predominantly expressed in the nucleus of AML blasts. A representative AML case with high SAMHD1 expression (>75%) (a). Morphology of blasts is shown by routine hematoxylin-eosin (H&E) stain of bone marrow section (b) and by May-Grünwald Giemsa (MGG) stain of bone marrow smear (b, inset) (original magnification ×400 for a, b (and ×600 for b, inset). c, d. A representative case of AML with low SAMHD1 expression (<25%) (c). Morphology of blasts is shown by H&E stain of bone marrow section (d) and by MGG stain of bone marrow smear (d, inset) (original magnification ×400 for c, d and ×600 for d, inset). e Examples of double immunostainings (SAMHD1/CD34) in two CD34+ AML cases, one with SAMHD1-/CD34+ blasts (left) and another with SAMHD1+/CD34+ blasts (right). (original magnification ×600; SAMHD1 in dark brown; CD34 in red). f Histogram showing the distribution of SAMHD1 expression level (% of positive blasts) in TMAs of AML patients

Back to article page